Graft-Versus Host Disease Market Set for Robust Expansion Through 2034, DelveInsight Reports | CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics., Novartis

The Key Graft-Versus-Host Disease Companies in the market include - CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others.

The Graft-Versus-Host Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graft-Versus-Host Disease pipeline products will significantly revolutionize the Graft-Versus-Host Disease market dynamics.

DelveInsight's "Graft-Versus-Host Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Graft-Versus-Host Disease, historical and forecasted epidemiology as well as the Graft-Versus-Host Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Graft-Versus-Host Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graft-Versus-Host Disease Market Forecast [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Graft-Versus-Host Disease Market Report:

*
The Graft-Versus-Host Disease market size was valued ~USD 1,301 million in 2023 and is anticipated to grow with a significant CAGR of 8.2% during the study period (2020-2034).

*
In June 2025, According to phase 3 BM12 CAST trial (ACTRN12618000505202) results presented at the 2025 European Hematology Association Congress, combining cyclophosphamide with cyclosporin, a calcineurin inhibitor, significantly enhanced graft-versus-host disease (GVHD)-free relapse-free survival (RFS) compared to standard prophylaxis in patients with aggressive blood cancers undergoing stem cell transplants from matched related donors with either reduced-intensity or myeloablative conditioning.

*
In March 2025, Signal12, Inc., a clinical-stage company specializing in ophthalmic pharmaceuticals, announced it has reached an agreement with the FDA regarding its Phase 3 clinical trial plan for Pro-ocular Trademark -an innovative, drop-free treatment designed to transform care for ocular Graft-versus-Host Disease (oGvHD).

*
In December 2024, The FDA approved Mesoblast's cell therapy, Ryoncil, for the treatment of graft-versus-host disease (GvHD) following stem cell or bone marrow transplantation. Ryoncil becomes the first mesenchymal stromal cell therapy authorized for use in pediatric patients as young as two months whose GvHD has not improved with standard steroid treatments.

*
In August 2024, AstraZeneca's IMFINZI (durvalumab) has been approved by the FDA for treating adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) that lacks known EGFR mutations or ALK rearrangements. The approved regimen involves using IMFINZI alongside neoadjuvant chemotherapy prior to surgery, followed by IMFINZI as a standalone adjuvant therapy post-surgery.

*
In 2023, the Graft Versus Host Disease treatment market in the US was valued at around USD 920 million and is expected to grow further with the introduction of new and emerging therapies.

*
In 2023, the combined Graft Versus Host Disease market size for the EU4 and the UK was estimated at about USD 252 million, representing nearly 19% of the total market revenue across the 7MM.

*
In 2023, Germany led the Graft Versus Host Disease Treatment Market within the EU4 and the UK, generating approximately USD 98 million. France was next with about USD 41 million, and the UK reported nearly USD 40 million.

*
In 2023, Japan's Graft Versus Host Disease Treatment Market Size was estimated at around USD 130 million and is expected to grow throughout the forecast period (2025-2034).

*
It is estimated that REZUROCK will generate around USD 173 million by 2034 across the 7MM.

*
DelveInsight estimates that in 2023, there were around 52,000 cases of Graft Versus Host Disease (GVHD) across the 7MM. The United States contributed to about 45% of these cases, while the EU4 countries and the UK collectively made up nearly 39%. Japan accounted for the remaining 16%.

*
According to DelveInsight's epidemiological model, around 57,000 allogeneic transplants and nearly 52,000 Graft Versus Host Disease (GVHD) cases were reported across the 7MM in 2023. These numbers are projected to rise by 2034.

*
In 2023, the United States recorded the highest number of Graft Versus Host Disease cases among the 7MM, with around 24,000 cases, and this count is anticipated to increase by 2034.

*
In 2023, Germany had the highest number of Graft Versus Host Disease cases among the EU4 and the UK, with an estimated 8,000 cases. Italy and France followed closely, each reporting around 3,000 cases, while Spain recorded the fewest, with approximately 2,700 cases.

*
In 2023, the United States recorded nearly 5,000 new cases of Graft Versus Host Disease, along with an estimated 18,000 prevalent cases accumulated over a five-year period.

*
In 2023, Germany documented roughly 900 Graft Versus Host Disease cases affecting the skin, around 400 involving the liver, and nearly 800 cases impacting the gastrointestinal tract.

*
Key Graft-Versus-Host Disease Companies: CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others

*
Key Graft-Versus-Host Disease Therapies: ZEMAIRA (CSL 964, alpha-1 antitrypsin), EQ001 (itolizumab; Bmab600), MaaT013, RGI-2001, Defibrotide, Ibrutinib, Panobinostat (LBH589), Natalizumab, Methoxsalen, Prograf, Prochymal Registered , Abatacept, RGI-2001, Axatilimab, Ruxolitinib, and others

*
In the United States in 2022, roughly 4,780 cases of acute Graft-versus-host disease (aGvHD) and approximately 17,210 cases of chronic Graft-versus-host disease (cGvHD) received first-line treatment. Projections suggest an anticipated increase in these cases by the year 2034.

*
The Graft-Versus-Host Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graft-Versus-Host Disease pipeline products will significantly revolutionize the Graft-Versus-Host Disease market dynamics.

Graft-Versus-Host Disease Overview

Graft-Versus-Host Disease (GVHD) is a condition that occurs after a bone marrow or stem cell transplant in which the donated (graft) immune cells attack the recipient's (host) body tissues. This reaction happens because the donor's immune cells recognize the recipient's cells as foreign and initiate an immune response against them.

Get a Free sample for the Graft-Versus-Host Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Graft-Versus-Host Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Graft-Versus-Host Disease Epidemiology Segmentation:

The Graft-Versus-Host Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Graft-Versus-Host Disease

*
Prevalent Cases of Graft-Versus-Host Disease by severity

*
Gender-specific Prevalence of Graft-Versus-Host Disease

*
Diagnosed Cases of Episodic and Chronic Graft-Versus-Host Disease

Download the report to understand which factors are driving Graft-Versus-Host Disease epidemiology trends @ Graft-Versus-Host Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Graft-Versus-Host Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graft-Versus-Host Disease market or expected to get launched during the study period. The analysis covers Graft-Versus-Host Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Graft-Versus-Host Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Graft-Versus-Host Disease Therapies and Key Companies

*
JAKAFI MOA/JAKAVI (ruxolitinib): Incyte

*
IMBRUVICA (ibrutinib): Pharmacyclics (acquired by AbbVie)/ Janssen

*
ZEMAIRA (CSL 964, alpha-1 antitrypsin): CSL Behring

*
EQ001 (itolizumab; Bmab600): Equillium/Biocon

*
CSL 964 AAT (zemaira): CSL Behring

*
MaaT013: MaaT Pharma

*
RGI-2001: Regimmune

*
Defibrotide: Jazz Pharmaceuticals

*
Ibrutinib: Pharmacyclics LLC.

*
Panobinostat (LBH589): Novartis

*
Natalizumab: Biogen

*
Methoxsalen: Mallinckrodt

*
Prograf: Astellas Pharma

*
Prochymal Registered : Mesoblast, Inc.

*
Abatacept: Thrasher Research Fund

*
RGI-2001: Regimmune Corporation

*
Axatilimab: Syndax Pharmaceutical

*
Ruxolitinib: Novartis

Discover more about therapies set to grab major Graft-Versus-Host Disease market share @ Graft-Versus-Host Disease Treatment Landscape [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Graft-Versus-Host Disease Market Strengths

*
Pipeline of GvHD is very robust and several late stage assets are expected to enter in to the market very soon. GvHD pipeline consists of small molecules, monoclonal and Bi-specific antibody, stem cell therapy, recombinant fusion protein etc. which will provide the patients and physicians more options in future.

Graft-Versus-Host Disease Market Opportunities

*
Several upcoming therapies have received Orphan designations, therapies can get accelerated approval time, 7 years of market exclusivity in the US, clinical trials subsidies and reduced regulatory fees and others. Company can also go for premium pricing as well.

Scope of the Graft-Versus-Host Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Graft-Versus-Host Disease Companies: CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others

*
Key Graft-Versus-Host Disease Therapies: ZEMAIRA (CSL 964, alpha-1 antitrypsin), EQ001 (itolizumab; Bmab600), MaaT013, RGI-2001, Defibrotide, Ibrutinib, Panobinostat (LBH589), Natalizumab, Methoxsalen, Prograf, Prochymal Registered , Abatacept, RGI-2001, Axatilimab, Ruxolitinib, and others

*
Graft-Versus-Host Disease Therapeutic Assessment: Graft-Versus-Host Disease current marketed and Graft-Versus-Host Disease emerging therapies

*
Graft-Versus-Host Disease Market Dynamics: Graft-Versus-Host Disease market drivers and Graft-Versus-Host Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Graft-Versus-Host Disease Unmet Needs, KOL's views, Analyst's views, Graft-Versus-Host Disease Market Access and Reimbursement

To know more about Graft-Versus-Host Disease companies working in the treatment market, visit @ Graft-Versus-Host Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Graft-Versus-Host Disease Market Report Introduction

2. Executive Summary for Graft-Versus-Host Disease

3. SWOT analysis of Graft-Versus-Host Disease

4. Graft-Versus-Host Disease Patient Share (%) Overview at a Glance

5. Graft-Versus-Host Disease Market Overview at a Glance

6. Graft-Versus-Host Disease Disease Background and Overview

7. Graft-Versus-Host Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Graft-Versus-Host Disease

9. Graft-Versus-Host Disease Current Treatment and Medical Practices

10. Graft-Versus-Host Disease Unmet Needs

11. Graft-Versus-Host Disease Emerging Therapies

12. Graft-Versus-Host Disease Market Outlook

13. Country-Wise Graft-Versus-Host Disease Market Analysis (2020-2034)

14. Graft-Versus-Host Disease Market Access and Reimbursement of Therapies

15. Graft-Versus-Host Disease Market Drivers

16. Graft-Versus-Host Disease Market Barriers

17. Graft-Versus-Host Disease Appendix

18. Graft-Versus-Host Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graftversus-host-disease-market-set-for-robust-expansion-through-2034-delveinsight-reports-csl-behring-equillium-biocon-maat-pharma-regimmune-jazz-pharmaceuticals-pharmacyclics-novartis]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.